Funding Opportunities

Team-Based Design in Biomedical Engineering Education (R25)

due: 13-05-2014 Training NIH PAR-13-111 Faculty required
This FOA, issued by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), encourages applications from institutions that propose to establish new or to enhance existing team-based design courses in undergraduate Biomedical Engineering departments or programs. This FOA targets undergraduate students at the senior level but may also include junior undergraduates and first-year graduate students. Courses that address innovative and/or ground-breaking development, multidisciplinary/interdisciplinary training and clincial immersion are especially encouraged.

Bioengineering Research Partnerships (BRP) R01

due: 20-05-2014 Research NIH PAR-14-092 US Citizen, Permanent Resident, Faculty required
This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical research problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing these technologies and engage biomedical researchers or clinicians throughout the project. The goal of the program is to support projects that can realize meaningful solutions within 5-10 years.

Bioengineering Research Grants (BRG) (R01)- PAR-13-137

due: 05-06-2014 Research NIH PAR-13-137 Faculty required
The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach that can increase our understanding of and solve problems in biological, clinical or translational science.

Exploratory/Developmental Bioengineering Research Grants (EBRG) [R21]

due: 05-06-2014 Research NIH PA-12-284 Faculty required
The purpose of this FOA is to encourage Exploratory/Developmental Bioengineering Research Grants (EBRG) applications which establish the feasibility of technologies, techniques or methods that: 1) explore a unique multidisciplinary approach to a biomedical challenge; 2) are high-risk but have a considerable pay-off; and 3) develop data which can lead to significant future research. An EBRG application may propose hypothesis-driven, discovery-driven, developmental, or design-directed research and is appropriate for evaluating unproven approaches for which there is minimal or no preliminary data.

Research Answers to NCI’s Provocative Questions- Group E (R21)- RFA-CA-13-025

due: 20-06-2014 Research NIH RFA-CA-13-025 Faculty required
Each application must address one and only one specific PQ from Group E, exactly as defined in this FOA. PQE1: (New for 2013) What strategies optimize adoption and sustainability of guideline concordant cancer treatments in community settings? PQE2: (New for 2013) What care delivery models can be developed to transition cancer patients effectively from active therapy to end of life care? PQE3: (New for 2013) What methods and approaches induce physicians and health systems to abandon ineffective interventions or discourage adoption of unproven interventions? PQE4: (New for 2013) What are the best methods to identify and stratify subgroups of patients with particular co-morbidities who will benefit from defined cancer therapies?